Total Payments
$140,973
2024 Payments
$35,834
Companies
33
Transactions
149
Medicare Patients
246
Medicare Billing
$63,555
Payment Breakdown by Category
Consulting$100,718 (71.4%)
Other$16,729 (11.9%)
Travel$13,090 (9.3%)
Food & Beverage$5,516 (3.9%)
Research$4,906 (3.5%)
Education$14.89 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $100,718 | 49 | 71.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $16,729 | 13 | 11.9% |
| Travel and Lodging | $13,090 | 14 | 9.3% |
| Food and Beverage | $5,516 | 67 | 3.9% |
| Unspecified | $4,906 | 5 | 3.5% |
| Education | $14.89 | 1 | 0.0% |
Payments by Type
General
$136,067
144 transactions
Research
$4,906
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| F. Hoffmann-La Roche AG | $39,952 | 18 | $0 (2021) |
| AstraZeneca UK Limited | $27,781 | 22 | $0 (2024) |
| Daiichi Sankyo Inc. | $15,285 | 23 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $11,133 | 11 | $0 (2024) |
| PFIZER INC. | $7,814 | 9 | $0 (2023) |
| Theratechnologies Inc. | $7,106 | 8 | $0 (2024) |
| Karyopharm Therapeutics Inc. | $5,000 | 1 | $0 (2021) |
| GENZYME CORPORATION | $4,580 | 4 | $0 (2022) |
| Seattle Genetics, Inc. | $3,798 | 6 | $0 (2019) |
| Eisai Inc. | $3,594 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $35,834 | 34 | AstraZeneca UK Limited ($13,770) |
| 2023 | $22,083 | 24 | AstraZeneca UK Limited ($6,707) |
| 2022 | $13,413 | 14 | GENZYME CORPORATION ($4,580) |
| 2021 | $14,723 | 7 | Karyopharm Therapeutics Inc. ($5,000) |
| 2020 | $1,369 | 3 | PFIZER INC. ($1,270) |
| 2019 | $34,349 | 26 | F. Hoffmann-La Roche AG ($26,175) |
| 2018 | $6,711 | 16 | F. Hoffmann-La Roche AG ($3,053) |
| 2017 | $12,491 | 25 | F. Hoffmann-La Roche AG ($8,408) |
All Payment Transactions
149 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/24/2024 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $953.75 | General |
| 12/19/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $3,759.00 | General |
| 12/10/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $149.85 | General |
| Category: ONCOLOGY | ||||||
| 11/06/2024 | AstraZeneca UK Limited | ENHERTU (Biological) | Consulting Fee | Cash or cash equivalent | $2,148.00 | General |
| Category: Oncology | ||||||
| 10/30/2024 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $1,090.00 | General |
| 10/28/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $2,953.50 | General |
| 10/01/2024 | Theratechnologies Inc. | — | Consulting Fee | Cash or cash equivalent | $350.00 | General |
| 09/24/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $1,611.00 | General |
| 09/14/2024 | AstraZeneca UK Limited | — | Food and Beverage | In-kind items and services | $76.14 | General |
| 08/26/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $97.85 | General |
| 07/31/2024 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $1,342.50 | General |
| 07/29/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $4,564.50 | General |
| 07/17/2024 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $1,635.00 | General |
| 07/08/2024 | Tempus AI, Inc | — | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| 07/03/2024 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $1,226.25 | General |
| 06/03/2024 | Daiichi Sankyo Inc. | — | Food and Beverage | In-kind items and services | $134.87 | General |
| 06/02/2024 | Theratechnologies Inc. | EGRIFTA (Drug), TROGARZO | Food and Beverage | In-kind items and services | $96.27 | General |
| Category: HIV | ||||||
| 05/01/2024 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $1,090.00 | General |
| 04/17/2024 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $1,090.00 | General |
| 04/01/2024 | Theratechnologies Inc. | — | Consulting Fee | Cash or cash equivalent | $700.00 | General |
| 03/28/2024 | Incyte Corporation | — | Consulting Fee | Cash or cash equivalent | $3,075.00 | General |
| 03/28/2024 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $278.25 | General |
| 03/28/2024 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $16.20 | General |
| 03/06/2024 | Theratechnologies Inc. | EGRIFTA (Drug), TROGARZO | Food and Beverage | In-kind items and services | $95.42 | General |
| Category: HIV | ||||||
| 03/06/2024 | Theratechnologies Inc. | EGRIFTA (Drug), TROGARZO | Travel and Lodging | In-kind items and services | $5.13 | General |
| Category: HIV | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ELRANATAMAB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| ONCOLOGY PORTFOLIO CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,270 | 2 |
| MY PATHWAY AN OPEN-LABEL PHASE IIA STUDY EVALUATING TRASTUZUMABPERTUZUMAB, ERLOTINIB, VEMURAFENIBCOBIMETINIB, VISMODEGIB , ALECTINIB AND ATEZOLIZUMAB IN PATIENTS WHO HAVE ADVANCED SOLID TUMORS WITH MUTATIONS OR GENE EXPRESSION ABNORMALITIES PREDICTIVE OF RESPONSE TO ONE OF THESE AGENTS | F. Hoffmann-La Roche AG | $336.15 | 1 |
| KRASG12C Inhibition in Advanced Solid Tumors | Amgen Inc. | $99.38 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 81 | 169 | $93,682 | $19,543 |
| 2022 | 2 | 68 | 143 | $74,994 | $17,589 |
| 2021 | 2 | 73 | 184 | $92,181 | $23,102 |
| 2020 | 1 | 24 | 36 | $17,247 | $3,321 |
Total Patients
246
Total Services
532
Medicare Billing
$63,555
Procedure Codes
7
All Medicare Procedures & Services
7 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 63 | 151 | $80,811 | $17,009 | 21.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 18 | 18 | $12,871 | $2,535 | 19.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 49 | 124 | $63,708 | $14,729 | 23.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 19 | 19 | $11,286 | $2,859 | 25.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 44 | 155 | $76,803 | $18,669 | 24.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 29 | 29 | $15,378 | $4,433 | 28.8% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 24 | 36 | $17,247 | $3,321 | 19.3% |
About Dr. Funda Meric, M.D
Dr. Funda Meric, M.D is a Surgical Oncology healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1306932074.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Funda Meric, M.D has received a total of $140,973 in payments from pharmaceutical and medical device companies, with $35,834 received in 2024. These payments were reported across 149 transactions from 33 companies. The most common payment nature is "Consulting Fee" ($100,718).
As a Medicare-enrolled provider, Meric has provided services to 246 Medicare beneficiaries, totaling 532 services with total Medicare billing of $63,555. Data is available for 4 years (2020–2023), covering 7 distinct procedure/service records.
Ad
Practice Information
- Specialty Surgical Oncology
- Other Specialties Surgery
- Location Houston, TX
- Active Since 10/04/2006
- Last Updated 11/26/2024
- Taxonomy Code 2086X0206X
- Entity Type Individual
- NPI Number 1306932074
Products in Payments
- Non-Covered Product (Drug) $24,279
- ENHERTU (Biological) $9,754
- Perjeta (Biological) $9,349
- Herceptin (Biological) $5,356
- XPOVIO (Drug) $5,000
- Halaven (Drug) $3,594
- ELREXFIO (Drug) $3,200
- DSP-0692 (Drug) $2,000
- Enhertu (Drug) $1,997
- GAVRETO (Drug) $1,980
- ADCETRIS (Biological) $1,875
- TECENTRIQ (Biological) $336.15
- Nerlynx (Drug) $214.49
- EGRIFTA (Drug) $196.82
- Xermelo (Drug) $142.64
- AFINITOR (Drug) $93.04
- FOUNDATIONONE (Device) $67.88
- Aliqopa (Drug) $66.82
- VERZENIO (Drug) $60.34
- LUMAKRAS (Drug) $24.18
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Surgical Oncology Doctors in Houston
Laurence Rhines, M.d, M.D
Surgical Oncology — Payments: $253,770
Surgical Oncology $253,770
Merrick Ross, M.d, M.D
Surgical Oncology — Payments: $241,432
Surgical Oncology $241,432
Kelly Hunt, M.d, M.D
Surgical Oncology — Payments: $84,139
Surgical Oncology $84,139
Jeffrey Gershenwald, M.d, M.D
Surgical Oncology — Payments: $81,481
Surgical Oncology $81,481
Lee Ellis, M.d, M.D
Surgical Oncology — Payments: $69,960
Surgical Oncology $69,960
Jean Vauthey, M.d, M.D
Surgical Oncology — Payments: $41,978
Surgical Oncology $41,978